To investigate whether Sp1 and Smad3 elicit a synergetic effect on TGF‐β‐induced upregulation of EGFR expression, on the basis of Smad3 knockdown, we used the Sp1 inhibitor MTM to treat breast cancer cells. The gene discussed is EGFR; the disease is breast cancer.